Breast cancer is the most common cancer among Indian women. The national figures, compiled from the Indian Council of Medical Research's National Cancer Registry Programme and GLOBOCAN data, are about 1,80,000 new cases and around 90,000 deaths every year. That is roughly one new diagnosis every three minutes and one death every six. The lifetime risk for an Indian woman is approximately 1 in 28, and that number is rising, particularly in urban India.

Two features make the Indian picture distinct. First, the age peak is younger. Western breast cancer most commonly presents in women in their late fifties and sixties; in India a meaningful share of cases occur between 35 and 45, a decade earlier than the Western average. The reasons are not fully understood — genetics, hormonal exposure, reproductive patterns, and lifestyle all contribute — but the practical implication is that Indian women cannot assume breast cancer is an older woman's disease.

Second, and more painfully, around 40 percent of Indian women with breast cancer present at stage III or IV — when the cancer has already locally advanced or metastasised. In countries with established screening programmes that figure is closer to 10 to 15 percent. Stage at diagnosis is the single biggest predictor of survival: stage I disease has roughly a 90 to 95 percent 5-year survival, stage IV has 25 to 30 percent. The gap between those two outcomes is largely about how early a woman walks into the clinic.

What is driving the rise in India is a combination of increasing life expectancy, urbanisation, later first pregnancies, fewer pregnancies overall, shorter breastfeeding durations, rising obesity, and longer hormonal exposure. None of these are reasons to feel guilty — they are simply the epidemiology, and they mean the next generation of Indian women needs better awareness and faster pathways to screening than the last.

• Ductal carcinoma in situ (DCIS) is the earliest, non-invasive form. Abnormal cells are confined to the lining of a milk duct and have not broken through. DCIS is almost always curable with surgery alone and is increasingly picked up on mammography rather than presenting as a lump.
• Lobular carcinoma in situ (LCIS) is non-invasive abnormal cell growth in the milk-producing lobules. It is not itself a cancer but is a marker of higher future breast cancer risk, and usually triggers close surveillance rather than aggressive treatment.
• Invasive ductal carcinoma is the commonest type, accounting for about 80 percent of all invasive breast cancers. It starts in a duct and has broken through into surrounding breast tissue, from where it can spread to lymph nodes and beyond.
• Invasive lobular carcinoma accounts for around 10 percent and starts in the lobules. It tends to grow in a more diffuse pattern that can make it harder to feel as a discrete lump and harder to see on mammography.
• Inflammatory breast cancer is uncommon but aggressive. It often presents without a lump — the breast becomes red, swollen, warm, and the skin takes on a pitted orange-peel appearance (peau d'orange). It is frequently misdiagnosed as mastitis at first and any breast inflammation that does not respond to antibiotics within a week or two needs urgent biopsy.
• Triple-negative breast cancer is defined by the absence of three receptors — oestrogen, progesterone, and HER2 — meaning it does not respond to hormonal therapy or HER2-targeted therapy. It is more common in younger Indian women and tends to be more aggressive, but newer chemotherapy and immunotherapy regimens are improving outcomes substantially.
• HER2-positive breast cancer has the HER2 protein over-expressed on the cancer cells. It used to carry a poor prognosis but now responds dramatically to targeted antibody therapies such as trastuzumab (Herceptin) and pertuzumab. Knowing the HER2 status is one of the single most important pieces of information on a breast biopsy report.

• Age is the biggest single risk factor everywhere — the risk rises sharply after 40 and again after 50. But in India the curve shifts younger, with a meaningful share of cases between 35 and 45, so age does not protect Indian women in their thirties the way it might elsewhere.
• Family history of breast or ovarian cancer in a first-degree relative (mother, sister, daughter), especially at a young age, raises personal risk significantly. BRCA1 and BRCA2 gene mutations are the strongest known inherited risk factors and account for a meaningful fraction of early-onset Indian cases.
• A personal history of breast cancer in one breast raises the risk of a new cancer in the other breast.
• Dense breasts (more glandular tissue than fat on mammography) raise risk and also make mammography harder to read. Indian women on average have denser breasts than the Western average, which is one of several reasons ultrasound is often used alongside mammography in India.
• Early menarche (first period before 12) and late menopause (after 55) both increase lifetime oestrogen exposure and raise risk modestly.
• Nulliparity (never having had a child) and late first pregnancy (after 30) raise risk, and each full-term pregnancy at a younger age provides some protection.
• Long-term combined oestrogen-and-progestogen hormone replacement therapy (HRT) for more than about five years modestly raises risk. The risk falls again after stopping.
• Postmenopausal obesity raises risk because fat tissue produces oestrogen. Premenopausal obesity has a more complex relationship.
• Alcohol consumption — even modest amounts — raises risk in a dose-dependent way. There is no safe amount that has been shown to be beneficial for the breast.
• Smoking raises risk, particularly in women who started smoking before their first full-term pregnancy.
• A sedentary lifestyle raises risk; regular physical activity (about 4 hours a week of moderate exercise) reduces it by 10 to 20 percent.
• A history of radiation therapy to the chest, particularly for Hodgkin's lymphoma in adolescence or young adulthood, raises risk significantly and warrants high-intensity surveillance starting at a young age.

• A new lump in the breast or armpit is the single most common presenting symptom and is what most women come in for. Most lumps are benign (fibroadenoma, cyst, fat necrosis, lipoma) but every new persistent lump deserves a clinical assessment, an ultrasound, and where indicated a mammogram and biopsy. For the most common benign mimic see fibroadenoma-of-the-breast-india.
• Skin changes — dimpling that pulls the skin inward like an orange peel (peau d'orange), thickening, redness that does not settle in a week, or ulceration in advanced disease — are all warning signs that need urgent investigation, not antibiotics and reassurance.
• Nipple changes are particularly important. New nipple inversion (the nipple pulling inward) in an adult who previously had a normal nipple, nipple retraction, persistent eczema-like changes around the nipple, or any nipple discharge that is bloody, spontaneous, single-duct, or unilateral all need investigation.
• A change in the size or shape of one breast, or new asymmetry that is clearly different from your baseline, is worth a visit.
• Persistent pain in one specific area of one breast, particularly if it does not move with your menstrual cycle, is worth investigating. Generalised breast pain that fluctuates with the cycle is overwhelmingly benign.
• Swelling of all or part of the breast, even without a discrete lump, can be a sign of inflammatory breast cancer and deserves urgent attention if it does not respond to a short course of antibiotics.
• The rule that matters: a new symptom that lasts more than a couple of weeks deserves a clinical exam, an ultrasound, and where indicated a mammogram. The vast majority of these workups end with reassurance. Indian women too often wait three to six months hoping a lump will disappear; the cost of waiting is measured in stage at diagnosis.

• Twenties: monthly breast self-examination starting in the twenties. Best done about a week after the period ends, when the breasts are least tender and least lumpy. The goal is not to catch cancer (most early cancers are too small to feel) but to learn your own breast map so that a new change announces itself clearly. See breast-self-exam-india for the technique step by step.
• Twenty-five to thirty onwards: an annual clinical breast examination by a doctor. This costs about 300 to 1,200 rupees at private clinics and is included in many corporate health checks and government health camps.
• Forty to fifty onwards: annual or biennial mammography for women at average risk. The National Health Mission in India recommends starting from 40 to 50 depending on resources, while most global guidelines start at 40 to 45 for average-risk women. Mammography costs roughly 1,000 to 3,500 rupees at private centres and is free or heavily subsidised at government teaching hospitals.
• Earlier and more frequent screening for higher risk: women with a known BRCA1 or BRCA2 mutation, a strong family history of early-onset breast or ovarian cancer, or a personal history of chest radiation typically start mammography 10 years earlier than the youngest affected family member, often with annual MRI added.
• Breast ultrasound (USG) is widely used in Indian practice, particularly in younger women with dense breasts where mammography is less informative, and as a follow-on when mammography or examination raises a question. Cost is around 500 to 2,500 rupees.
• Breast MRI is the most sensitive test, used for BRCA-positive and other very high-risk women, and to evaluate complex findings. Cost is roughly 5,000 to 15,000 rupees at private centres, less at government and teaching hospitals.
• What screening cannot do: replace symptom awareness. A normal mammogram does not mean you can ignore a new lump that develops three months later. Between-screening interval cancers do happen, and your own monthly self-check is the best safety net for them.

When a woman walks into an Indian breast clinic with a lump, a skin change, or an abnormal mammogram, the diagnostic pathway has a fairly standard shape. It starts with a thorough clinical breast examination — both breasts and both armpits, with the woman sitting up and lying down. The doctor notes the size, location, mobility, consistency, and surface of any lump, as well as any skin or nipple change and any palpable lymph nodes.

Imaging usually follows immediately. Ultrasound is the first investigation in women under 35 to 40 and in pregnancy; it is excellent at telling apart a simple cyst (almost always benign) from a solid mass that needs further workup. Mammography is added for women 40 and over and for any solid mass picked up on ultrasound. The radiologist categorises the finding using the BI-RADS scale from 1 (negative) to 5 (highly suspicious of malignancy), with 6 reserved for biopsy-proven cancer.

Anything BI-RADS 4 or 5 needs tissue. The cheapest option is fine needle aspiration cytology (FNAC), where a thin needle draws cells out of the lump for the cytopathologist to look at under a microscope. FNAC costs roughly 500 to 1,500 rupees and gives a quick answer for cystic lesions and some clearly benign or clearly malignant solid lumps, but it does not preserve tissue architecture.

Core needle biopsy is the standard for any suspicious solid lesion. A wider hollow needle takes one or more cores of tissue under ultrasound or mammographic guidance, costs roughly 2,000 to 5,000 rupees, and provides enough tissue to make a definitive diagnosis and to run all the receptor tests.

Receptor testing is performed on the biopsy tissue and is essential for treatment planning. Three receptors are tested: oestrogen receptor (ER), progesterone receptor (PR), and HER2. Each test costs roughly 2,000 to 8,000 rupees at private labs. The combination of these three receptors plus the grade and the tumour size tells the oncologist whether to plan hormonal therapy, HER2-targeted therapy, or chemotherapy, and in what order.

BRCA1 and BRCA2 genetic testing is added for women under 50, women with a strong family history of breast or ovarian cancer, women with triple-negative disease, and women with a personal history of multiple primary cancers. In India, BRCA panel testing typically costs 15,000 to 50,000 rupees at private labs such as MedGenome, Mapmygenome, Strand, and Centogene, with PMJAY coverage available at some empanelled cancer centres.

The major Indian laboratory networks that handle most of these tests include Thyrocare, Metropolis, SRL, and Apollo Diagnostics, with cancer-specialised testing at the major comprehensive cancer centres and dedicated molecular labs.

• Breast cancer is staged using the TNM system — T for tumour size, N for lymph node involvement, M for distant metastasis — combined into an overall Stage 0 to IV. Stage is the single most important predictor of survival and of how aggressive treatment will need to be.
• Stage 0 is DCIS or LCIS — non-invasive disease confined to the duct or lobule. 5-year survival is essentially 100 percent with appropriate treatment.
• Stage I is a small invasive tumour (under 2 cm) with no lymph node involvement and no spread. 5-year survival is around 90 to 95 percent.
• Stage II is either a larger tumour without lymph nodes, or a smaller tumour with limited lymph node involvement. 5-year survival is around 80 to 90 percent.
• Stage III is locally advanced disease — larger tumour, extensive lymph node involvement, skin or chest-wall invasion, or inflammatory breast cancer. 5-year survival is around 50 to 70 percent depending on the subtype and response to treatment.
• Stage IV is metastatic disease — the cancer has spread to distant organs such as bone, liver, lung, or brain. 5-year survival is around 25 to 30 percent, though for hormone-receptor-positive and HER2-positive disease modern targeted therapy has substantially extended survival.
• The number that should drive Indian conversations about breast cancer is not the metastatic survival number. It is the gap between stage I and stage III — 90 to 95 percent versus 50 to 70 percent — and the fact that 40 percent of Indian women are still presenting at stage III or IV.

• Surgery is part of treatment for nearly every breast cancer. The two main options are lumpectomy (breast-conserving surgery, in which only the tumour and a margin of healthy tissue is removed) and mastectomy (the whole breast is removed). Lumpectomy is generally followed by radiation. The choice between them depends on tumour size relative to breast size, multiple tumour locations, ability to receive radiation, patient preference, and BRCA status.
• Sentinel lymph node biopsy is the modern standard for assessing whether the cancer has spread to the armpit lymph nodes. A few key nodes are removed and examined; if they are clear, the rest of the lymph nodes can usually be left alone. This dramatically reduces the risk of lymphoedema — the chronic arm swelling that used to be common after older-style full axillary lymph node dissection.
• Axillary lymph node dissection is reserved for cases where multiple sentinel nodes are positive or there is clear clinical involvement, and it carries a higher lymphoedema risk that needs ongoing physiotherapy attention.
• Chemotherapy is given either before surgery (neoadjuvant) to shrink the tumour and make breast conservation possible, or after surgery (adjuvant) to kill any micro-metastatic cells that may have left the breast before the operation. The commonest regimen is AC-T — doxorubicin (Adriamycin) and cyclophosphamide followed by a taxane such as paclitaxel or docetaxel — given in cycles over four to six months. Cost per cycle in the Indian private sector runs roughly 15,000 to 2,00,000 rupees depending on the regimen and centre; government cancer hospitals provide it free or at heavily subsidised rates.
• Radiation therapy is essentially always given after lumpectomy and is added after mastectomy when the lymph nodes are positive or the tumour was large. The standard course is 25 to 30 daily sessions over about five to six weeks, with modern shorter (hypofractionated) schedules increasingly common. Cost in the private sector is roughly 50,000 to 3,00,000 rupees for a full course; government and PMJAY pricing is dramatically lower.
• Side effects of chemotherapy include hair loss, fatigue, nausea, low blood counts with infection risk, and peripheral neuropathy from the taxanes. Side effects of radiation include skin redness and tiredness during the course and a small long-term risk of cardiac and lung effects depending on the field. Both sets of side effects are temporary for the most part and are actively managed throughout treatment.

• Hormonal therapy is used for ER-positive and PR-positive breast cancers — together about 70 percent of all breast cancers. In premenopausal women, the standard is tamoxifen for 5 to 10 years (cost roughly 50 to 200 rupees per month). In postmenopausal women, aromatase inhibitors such as anastrozole or letrozole are preferred (cost roughly 100 to 500 rupees per month). Both classes substantially reduce the risk of recurrence and of new cancers in the other breast.
• Ovarian suppression with a GnRH agonist such as goserelin is added for some premenopausal women with higher-risk disease, effectively switching off oestrogen production from the ovaries during treatment.
• HER2-targeted therapy revolutionised the outlook for HER2-positive disease. Trastuzumab (Herceptin) is the foundation drug, given intravenously every three weeks for a year, often combined with pertuzumab in higher-risk cases. The cost per dose in India runs roughly 5,000 to 25,000 rupees depending on the brand (originator vs biosimilar), and patient assistance programmes from the manufacturers, PMJAY at empanelled centres, and biosimilars from Indian companies have made it much more accessible than a decade ago.
• PARP inhibitors such as olaparib are used for women with BRCA1 or BRCA2 mutations whose cancer has progressed or who are at high risk of recurrence. They are oral targeted drugs and are particularly valuable for triple-negative BRCA-positive disease.
• Immunotherapy with pembrolizumab is now part of standard treatment for high-risk triple-negative breast cancer in combination with chemotherapy, and has significantly improved outcomes for this previously hard-to-treat subgroup.
• Costs for targeted therapy and immunotherapy in the Indian private sector run from roughly 50,000 to 3,00,000 rupees per month and are one of the major financial burdens of breast cancer treatment. PMJAY's 5 lakh annual cover, manufacturer assistance schemes, biosimilars, generic launches as patents expire, and corporate health insurance all matter, and a hospital's medical social worker is often the best first conversation about how to put a payment package together.

• Ayushman Bharat PMJAY covers breast cancer surgery, chemotherapy, radiation, and most diagnostic workup for eligible families up to 5 lakh rupees a year. Cashless treatment is available at empanelled hospitals across India. The annual limit may not cover the full course in a complex case, but it covers the majority of standard treatment.
• Comprehensive cancer centres are where breast cancer should ideally be treated, because stage III and IV survival in particular depends heavily on the experience of the multidisciplinary team. The national leaders include Tata Memorial Hospital (Mumbai), the AIIMS network (Delhi, Bhubaneswar, Bhopal, Jodhpur, Patna, Raipur, Rishikesh and the new AIIMS), Christian Medical College (CMC) Vellore, JIPMER Puducherry, alongside private cancer chains and units such as HCG, Apollo Cancer, Fortis Cancer, and Manipal Comprehensive Cancer Centre.
• Surgery cost in the private sector typically runs 50,000 to 3,00,000 rupees depending on the procedure (lumpectomy vs mastectomy, reconstruction), the surgeon, and the hospital. Public sector and PMJAY pricing is dramatically lower.
• Chemotherapy per cycle runs roughly 15,000 to 2,00,000 rupees privately depending on the drugs and admission; government cancer hospitals provide it at very low or no cost. A full course is typically 4 to 8 cycles.
• Radiation therapy runs roughly 50,000 to 3,00,000 rupees for a full course privately; government and PMJAY pricing is much lower.
• Targeted therapy is the most expensive piece — 50,000 to 3,00,000 rupees per month is common for trastuzumab and the newer agents. Biosimilars have brought the trastuzumab cost down substantially. Manufacturer patient assistance programmes are worth asking about explicitly.
• Tamoxifen and aromatase inhibitor tablets are inexpensive (50 to 500 rupees per month) and are usually the smallest line of the bill.

BRCA1 and BRCA2 genetic testing is one of the most powerful tools available to Indian families with a strong personal or family history of breast or ovarian cancer. A positive result does not mean cancer will happen, but the lifetime breast cancer risk for a BRCA1 or BRCA2 carrier is roughly 50 to 70 percent (compared to around 12 percent for the general population), and the ovarian cancer risk is roughly 15 to 60 percent. Knowing the result allows several powerful preventive options to be considered.

Testing should be considered for women with breast cancer diagnosed under 50, triple-negative breast cancer at any age, male breast cancer in the family, multiple primary cancers (breast and ovarian, or bilateral breast), a first-degree relative with breast or ovarian cancer at a young age, or a known BRCA-positive relative.

The test is a blood draw or saliva sample. In India, BRCA1 and BRCA2 panel testing typically costs 15,000 to 50,000 rupees at private labs such as MedGenome, Mapmygenome, Strand, Centogene, and Lal PathLabs partners. Larger hereditary cancer panels that also cover Lynch syndrome and other genes are available at the higher end. PMJAY covers genetic testing at some empanelled cancer centres.

Pre-test and post-test genetic counselling is the most important part of the process. A counsellor or specialist explains what positive, negative, and variant-of-uncertain-significance results mean, what they imply for the woman herself, and what they imply for her sisters, daughters, and other relatives. Testing without counselling can cause real harm; testing with counselling can change family futures.

For a BRCA-positive woman, the preventive options include high-intensity surveillance (annual MRI plus mammography starting in the late twenties or early thirties), chemoprevention with tamoxifen or raloxifene, risk-reducing mastectomy (which cuts breast cancer risk by around 90 percent), and risk-reducing salpingo-oophorectomy after childbearing (which cuts ovarian cancer risk by 80 to 95 percent and also lowers breast cancer risk). None of these is mandatory; all are choices the woman makes with her care team.

• Myth: breast cancer only happens to older women. Fact: in India a meaningful share of cases occur between 35 and 45, a decade earlier than the Western average. Indian women in their thirties cannot assume breast cancer is somebody else's problem.
• Myth: every lump is cancer. Fact: most breast lumps in younger women are benign — fibroadenomas, simple cysts, fat necrosis, lipomas. The aim is not to panic over every lump but to have every persistent new lump assessed. See fibroadenoma-of-the-breast-india for the most common benign mimic.
• Myth: antiperspirants and deodorants cause breast cancer. Fact: this has been investigated extensively and no link has been found. Choose what you like.
• Myth: wearing a bra (especially an underwire bra) causes breast cancer. Fact: there is no evidence for this. Tight clothing does not cause breast cancer.
• Myth: mammography itself causes breast cancer because of the radiation dose. Fact: the radiation dose from a screening mammogram is very low — comparable to a few months of natural background radiation — and the benefit in detecting early cancer in the screening age groups far outweighs the theoretical risk.
• Myth: any breast inflammation in a non-breastfeeding woman is just mastitis and antibiotics will fix it. Fact: inflammatory breast cancer can mimic mastitis exactly, and any breast inflammation that does not respond to a short antibiotic course needs urgent biopsy. For lactation-related mastitis the picture is different — see mastitis-blocked-duct-breastfeeding-india.
• Myth: vaccines (including the HPV vaccine) cause breast cancer. Fact: there is no link. The HPV vaccine prevents cervical, vulvar, vaginal, anal, and head and neck cancers — see The HPV Vaccine in India: Cervavac, Gardasil, and What Every Family Should Know and the broader cervical picture in cervical-cancer-india-screening.
• Myth: if no one in my family has had it, I cannot get breast cancer. Fact: around 80 to 90 percent of breast cancers occur in women with no significant family history. Being low family-risk does not mean being no-risk.